Enhancement of antibody-mediated immune responses

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S141100, C424S155100, C424S156100

Reexamination Certificate

active

07416726

ABSTRACT:
The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo.

REFERENCES:
patent: 4752601 (1988-06-01), Hahn
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5476786 (1995-12-01), Huston
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5637687 (1997-06-01), Wiggins
patent: 5648260 (1997-07-01), Winter et al.
patent: 5677437 (1997-10-01), Teng et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5780607 (1998-07-01), Goodnow, Jr. et al.
patent: 5783682 (1998-07-01), Cook et al.
patent: 5792844 (1998-08-01), Sanghvi et al.
patent: 5811234 (1998-09-01), Roninson et al.
patent: 5814500 (1998-09-01), Dietz
patent: 5834597 (1998-11-01), Tso et al.
patent: 5981229 (1999-11-01), Masure et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025198 (2000-02-01), Bennett et al.
patent: 6028053 (2000-02-01), van der Geer et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 2012311 (1990-09-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 92/05263 (1992-04-01), None
patent: WO 94/21807 (1994-09-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 95/18863 (1995-07-01), None
patent: WO 95/21931 (1995-08-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 96/17823 (1996-06-01), None
patent: WO 96/25508 (1996-08-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/05787 (1998-02-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/01157 (1999-01-01), None
patent: WO 99/01158 (1999-01-01), None
patent: WO 99/01175 (1999-01-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/15214 (2000-03-01), None
Colman et al., Research in Immunology (145(1):33-36, 1994.
Abaza et al., Journal of Protein Chemistry (11(5):433-444, 1992.
Lederman et al Molecular Immunology (28:1171-1181, 1991.
Li et al PNAS 77:3211-3214, 1980.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Pearse et al., Immunol., 1999, vol. 10, pp. 753-760.
Gupta, N., et al., “Negative signaling pathways of the killer cell inhibitory receptor and FcγIIb1 require distinct phosphatases,”J. Experimental Medicine, 1997, 186(3), 473-478.
Baselga, J., et al., “Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2
euoverexpressing human breast cancer xenografts,”Cancer Res., Jul. 1, 1998, 58, 2825-2831.
Bird, R.E., et al., “Single-chain antigen-binding proteins,”Science, Oct. 21, 1988, 242, 423-426.
Boder, E.T., et al., “Yeast surface display for screening combinatorial polypeptide libraries,”Nat. Biotechnol., Jun. 1997, 15, 553-557.
Bolland, S., et al., “SHIP modulates immune receptor responses by regulating membrane association of Btk,”Immunity, Apr. 1998, 8, 509-516.
Brooks, D.G., et al., “Structure and expression of human IgG FcRII(CD32) functional heterogeneity is encoded by the alternatively spliced products of multiple genes,”J. Exp. Med., Oct. 1989, 170, 1369-1385.
Buchwald, H., et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in the ambulatory patients with recurrent venous thrombosis,”Surgery, Oct. 1980, 88(4), 507-516.
Burton, D.R., “Immunoglobulin G: functional sites,”Mol. Immunol., 1985, 22(3), 161-206.
Capel, P.J.A., et al., “Heterogeneity of human IgG Fc receptors,”Immunomethods, 1994, 4, 25-34.
Carter, P., et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA, May 1992, 89, 4285-4289.
Clackson, T., et al., “Making antibody fragments using phage display libraries,”Nature, Aug. 15, 1991, 352, 624-628.
Cochet, O., et al., “Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression,”Cancer Res.,Mar. 15, 1998, 58, 1170-1176.
Cox, A.L., et al., “Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines,”Science, Apr. 29, 1994, 264, 716-719.
Curiel, D.T., et al., “High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes,”Hum. Gene Ther., 1992, 3, 147-154.
Curiel, D.T., “Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies,” Gene Therapy Program,Advances in Pharmacology, 1997, 40, 51-84.
Daëron, M., “Fc receptor biology,”Annu. Rev. Immunol., 1997, 15, 203-234.
Damen, “The 145-kDa protein induced to associate with She by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase,”Proc. Natl. Acad. Sci. USA, 1996, 93, 1681693.
de Haas, M., et al., “Fcγ receptors of phagocytes,”J. Lab. Clin. Med., 1995, 126, 330-341.
Deisenhofer, J., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A fromStaphylococcus aureusat 2.9- and 2.8-Å resolution,”Am. Chem. Soc., Apr. 28, 1981, 20(9), 2361-2370.
During, M.J., et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,”Ann. Neurol., 1989, 25, 351-356.
Ellman, J., et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins,”Meth. In Enzym., 1991, 202, 301-336.
Felgner, P.L., et al., “Cationic liposome-mediated transfection,”Nature, Jan. 26, 1989, 337, 387-388.
Felgner, P.L., et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, Nov. 1987, 84, 7413-7417.
Goodson, J.M., inMedical Applications of Controlled Release, 1984, vol. 2, 115-138.
Han, D.C., et al., “Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice,”Am. J. Physiol. Renal Physiol., 2000, 278, F628-F634.
Hanna, A.K., et al., “Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts,”J. Vasc. Surg., 2000, 31, 770-780.
Howard, M.A., et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg., 1989, 71, 105-112.
Huse, W.D., et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambada,”Science, Dec. 8, 1989, 246, 1275-1281.
Huston, J.S., et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli, Proc. Natl. Acad. Sci. USA, Aug. 1988, 85, 58

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Enhancement of antibody-mediated immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of antibody-mediated immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of antibody-mediated immune responses will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4019106

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.